Pharmacological treatment of adolescent pathological gambling

International Journal of Adolescent Medicine and Health

Volumn 22, Issue 1, 2010, Pages 129-138

  Grant, Jon E ^a   Potenza, Marc N ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adolescence; Impulse control disorders; Pathological gambling; Pharmacotherapy

Indexed keywords

ACETYLCYSTEINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DESIPRAMINE; FLUVOXAMINE; LITHIUM; MOOD STABILIZER; NALMEFENE; NALTREXONE; NEUROLEPTIC AGENT; OLANZAPINE; OPIATE ANTAGONIST; PAROXETINE; RISPERIDONE; SERTRALINE; ZIPRASIDONE;

ADOLESCENT; ALCOHOLISM; AUTISM; CHILD BEHAVIOR; CLINICAL TRIAL; DIZZINESS; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FLATULENCE; FOOD AND DRUG ADMINISTRATION; HEART DISEASE; HIGH RISK POPULATION; HUMAN; LIMBIC SYSTEM; NAUSEA; PATHOLOGICAL GAMBLING; PRACTICE GUIDELINE; PSYCHOTHERAPY; REVIEW; SOMNOLENCE; SUICIDAL BEHAVIOR; UNITED STATES; XEROSTOMIA;

ADOLESCENT; ADOLESCENT BEHAVIOR; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ADDICTIVE; EXCITATORY AMINO ACID AGENTS; GAMBLING; HUMANS; NARCOTIC ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; UNITED STATES;

EID: 77952349234     PISSN: 03340139     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Wagner FA, Anthony JC. From first drug use to drug dependence: developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropsychopharmacology 2002;26:479-488
2. Chambers RA, Potenza MN. Neurodevelopment, impulsivity, and adolescent gambling. J Gambl Stud 2003;19:53-84.
3. th-grade students. J Pediatr 1998;102: e23.
4. Romer D, ed. Reducing adolescent risk: toward an integrated approach. Thousand Oaks, CA: Sage Publications, 2003.
5. Wallisch L. Gambling in Texas: 1992 Texas survey of adolescent gambling behavior. Austin, TX: Texas Commission Alcohol Drug Abuse, 1993.
6. Gupta R, Derevensky JL. Adolescent gambling behavior: A prevalence study and examination of the correlates associated with problem gambling. J Gambl Stud 1998;14:319-345 (Pubitemid 128533817)
7. Stinchfield R. A comparison of gambling among Minnesota public school students in 1992, 1995 and 1998. J Gambl Stud 2001;17:273-296
8. Chambers RA, Taylor JR, Potenza MN. Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. Am J Psychiatry 2003;160:1041-1052
9. Shaffer HJ, Hall MN. Estimating the prevalence of adolescent gambling disorders: a quantitative synthesis and guide toward standard gambling nomenclature. J Gambl Stud 1996;12:193-214.
10. Derevensky JL, Gupta R. Prevalence estimates of adolescent gambling: a comparison of the SOGS-RA, DSM-IV-J, and the GA 20 questions. J Gambl Stud 2000;16:227-251
11. rd ed. New York: Oxford Univ Press, 2007:561-577
12. Grant JE, Kim SW, Hartman BK. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry 2008;69:783-789
13. Grant JE, Kim SW, Hollander E, Potenza MN. Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. Psychopharmacology (Berl) 2008;200:521-527
14. Campbell M, Anderson LT, Small AM, Adams P, Gonzalez NM, Ernst M. Naltrexone in autistic children: behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry 1993;32: 1283-1291
15. Lifrak PD, Alterman AI, O'Brien CP, Volpicelli JR. Naltrexone for alcoholic adolescents. Am J Psychiatry 1997;154:439-441
16. Hollander E, Frenkel M, DeCaria C, Trungold S, Stein DJ. Treatment of pathological gambling with clomipramine [letter]. Am J Psychiatry 1992;149:710-711
17. Flament MF, Rapoport JL, Berg CJ, Sceery W, Kilts C, Mellstrom B, et al. Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study. Arch Gen Psychiatry. 1985;42:977-983
18. Leonard HL, Swedo SE, Rapoport JL, Koby EV, Lenane MC, Cheslow DL, et al. Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. A double-blind crossover comparison. Arch Gen Psychiatry 1989;46:1088-1092
19. DeVeaugh-Geiss J, Moroz G, Biederman J, Cantwell D, Fontaine R, Greist JH, et al. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder - a multicenter trial. J Am Acad Child Adolesc Psychiatry 1992;31;45-49
20. Riddle MA, Reeve EA, Yaryura-Tobias JA, Yang HM, Claghorn JL, Gaffney G, et al. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 2001;40:222-229 (Pubitemid 32111026)
21. Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized controlled trial. J Am Acad Child Adolesc Psychiatry 2001;40:762. (Pubitemid 32595260)
22. Abbott A. British panel bans use of antidepressant to treat children. Nature 2003;423:792.
23. Emslie GJ, Ventura D, Korotzer A, Tourkodimitris S. Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multi-site trial. J Am Acad Child Adolesc Psychiatry 2009;48:721-729
24. Black DW, Arndt S, Coryell WH, Argo T, Forbush KT, Shaw MC, et al. Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study. J Clin Psychopharmacology 2007;27:143-150
25. Geller B, Cooper TB, Sun K, Zimerman B, Frazier, J, Williams, M, et al. Double-blind and placebo-controlled study of lithium for adoles-cent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry 1998;37:171-178
26. Potenza MN, McDougle CJ. The potential of atypical antipsychotics in the treatment of non-psychotic disorders. CNS Drugs 1998;9:213-232 (Pubitemid 28154810)
27. McElroy SL, Nelson EB, Welge JA, Kaehler L, Keck PE Jr. Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial. J Clin Psychiatry 2008;69(3):433-440 (Pubitemid 351549397)
28. Fong T, Kalechstein A, Bernhard B, Rosenthal R, Rugle L. A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers. Pharmacol Biochem Behav 2008;89:298-303.
29. Stigler KA, Potenza MN, McDougle CJ. Tolerability profile of atypical antipsychotics in children and adolescents. Pediatr Drugs 2001;3:927-942
30. Kalivas PW, Peters J, Knackstedt L. Animal models and brain circuits in drug addiction. Mol Interv 2006;6:339-344 (Pubitemid 46046944)
31. Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry 2007;62:652-657
32. Bloom B, Cohen RA, Freeman G. Summary health statistics for U.S. children: National Health Interview Survey, 2007. Vital Health Stat 10. 2009;239:1-80.
33. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 1993;50:565-576
34. Specker SM, Carlson GA, Christenson GA, Marcotte M. Impulse control disorders and attention deficit disorder in pathological gamblers. Ann Clin Psychiatry 1995;7:175-179 (Pubitemid 26105850)
35. Brennan AR, Arnsten AF. Neuronal mechanisms underlying attention deficit hyperactivity disorder: the influence of arousal on prefrontal cortical function. Ann N Y Acad Sci 2008;1129:236-245
36. Potenza MN, Leung HC, Blumberg HP, Peterson BS, Fulbright RK, Lacadie CM, et al. An FMRI stroop task study of ventromedial prefrontal cortical function in pathological gamblers. Am J Psychiatry 2003;160:1990-1994
37. Chamberlain SR, Sahakian BJ. The neuropsychiatry of impulsivity. Curr Opin Psychiatr 2007;20:255-261
38. DeVito EE, Blackwell AD, Kent L, Ersehe KD, Clark L, Salmond CH, et al. The effects of methylphenidate on decision making in attention-deficit/ hyperactivity disorder. Biol Psychiatry 2008;64; 636-639
39. Carroll KM. Integrating psychotherapy and pharmacotherapy to improve drug abuse treatment outcome. Addict Behav 1997;22: 233-245